Zhejiang Huahai Pharmaceutical Co., Ltd.

SHSE:600521 Stock Report

Market Cap: CN¥26.9b

Zhejiang Huahai Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Zhejiang Huahai Pharmaceutical has been growing earnings at an average annual rate of 11.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 11.4% per year. Zhejiang Huahai Pharmaceutical's return on equity is 12.7%, and it has net margins of 12.2%.

Key information

11.5%

Earnings growth rate

10.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate11.4%
Return on equity12.7%
Net Margin12.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06
There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Recent updates

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Oct 22
Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Sep 25
Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28
Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06
There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22
Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Revenue & Expenses Breakdown

How Zhejiang Huahai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600521 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,3491,1403,0421,003
30 Jun 249,1431,0102,917996
31 Mar 248,7489282,757995
31 Dec 238,3098302,584983
30 Sep 238,6351,0952,582922
30 Jun 238,7361,1692,729913
31 Mar 238,5521,2032,605910
31 Dec 228,2661,1682,579926
30 Sep 227,8846922,6171,043
30 Jun 227,4325402,5531,023
31 Mar 226,9193702,5471,006
31 Dec 216,6444882,463942
30 Sep 216,2126792,325757
30 Jun 216,2158672,153694
31 Mar 216,4129642,096603
31 Dec 206,4859302,109566
30 Sep 206,2478981,969532
30 Jun 206,0418132,041503
31 Mar 205,7606551,999485
31 Dec 195,3885701,846467
30 Sep 195,2633642,110429
30 Jun 195,2092132,090410
31 Mar 195,055812,170411
31 Dec 185,0951082,154397
30 Sep 185,3354091,861398
30 Jun 185,1905731,548536
31 Mar 185,1126611,474437
31 Dec 175,0026391,543353
30 Sep 174,6806011,624237
30 Jun 174,4605371,7780
31 Mar 174,2545191,6420
31 Dec 164,0935011,4950
30 Sep 164,0014921,4230
30 Jun 163,8484661,3720
31 Mar 163,7384641,2590
31 Dec 153,5004421,1660
30 Sep 153,2013999920
30 Jun 153,0713729000
31 Mar 152,7933138360
31 Dec 142,5852667960
30 Sep 142,4062777020
30 Jun 142,2202656490
31 Mar 142,2243105980
31 Dec 132,2963595550

Quality Earnings: 600521 has high quality earnings.

Growing Profit Margin: 600521's current net profit margins (12.2%) are lower than last year (12.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600521's earnings have grown by 11.5% per year over the past 5 years.

Accelerating Growth: 600521's earnings growth over the past year (4.1%) is below its 5-year average (11.5% per year).

Earnings vs Industry: 600521 earnings growth over the past year (4.1%) exceeded the Pharmaceuticals industry -1.2%.


Return on Equity

High ROE: 600521's Return on Equity (12.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies